This paper tests the contribution of the toll-like receptors, TLR4 in particular, in the initiation
and maintenance of paclitaxel-related chemotherapy-induced peripheral neuropathy. TLR4 …

Abstract Toll-like receptor 4 (TLR4) has been implicated as a locus for initiation of paclitaxel
related chemotherapy induced peripheral neuropathy (CIPN). This project explores the …

Chemotherapy-induced peripheral neuropathy (CIPN) remains a pressing clinical problem;
however, our understanding of sexual dimorphism in CIPN remains unclear. Emerging …

Paclitaxel, a powerful anti-neoplastic drug, often causes pathological pain, which
significantly reduces the quality of life in patients. Paclitaxel-induced pain includes pain that …

Chemotherapy-induced peripheral neuropathy (CIPN) is a disruptive and persistent side
effect of cancer treatment with paclitaxel. Recent reports showed that paclitaxel treatment …

Patients receiving paclitaxel for cancer treatment often develop an acute pain syndrome
(paclitaxel‐associated acute pain syndrome, P‐APS), which occurs immediately after …

Background Neuropathic pain is a common complication of treatment with the anti‐
neoplastic drug paclitaxel. Animal studies suggest neuroinflammation and transient receptor …

Paclitaxel is a commonly used cancer chemotherapy drug that frequently causes painful
peripheral neuropathies. The mechanisms underlying this dose-limiting side effect are …

Peripheral neuropathy is dose limiting in paclitaxel cancer chemotherapy and can result in
both acute pain during treatment and chronic persistent pain in cancer survivors. The …

Peripheral neuropathy is one of the most common side effects of chemotherapy, affecting up
to 60% of all cancer patients receiving chemotherapy. Moreover, paclitaxel induces …